Abstract
The conclusive diagnosis of neurodegenerative diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD), has been predominantly clinical and, in these cases, the neurodegeneration is already installed in the patient's brain. Therefore, efforts have been made to identify molecular biomarkers for early diagnosis and monitoring these neurodegenerations progression. High perform…